Delwyn D. Miller, MD

Portrait
Professor of Psychiatry

Contact Information

Office
1-291 Medical Education Building
Iowa City, IA 52242
319-353-4506

Education

BS, Pharmacy, University of Iowa College of Pharmacy, Iowa City, IA
PharmD, Pharmacy, University of Kentucky College of Pharmacy, Lexington, KY
MD, Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
Resident, Hospital and Clinical Pharmacy, University of Kentucky Hospitals and Clinics
Resident, Psychiatry, University of Iowa Hospitals and Clinics, Department of Psychiatry, Iowa City, IA
Fellow, University of Iowa Carver College of Medicine, Iowa City, IA
Fellow, Schizophrenia, Mental Health Clinical Research Center for the Study of Schizophrenia, University of Iowa Hospitals and Clinics, Iowa City, IA
Postdoctoral Fellow, University of Iowa Carver College of Medicine, Iowa City, IA

Licensure and Certifications

Psychiatry certification - American Board of Psychiatry and Neurology

Publications

Buckley, P. F., Schooler, N. R., Goff, D. C., Hsiao, J., Kopelwicz, A., Lauriello, J., Manschreck, T., Mendelowitz, A. J., Miller, D. D., Severe, J. B., Wilson, D. R., Ames, D., Bustillo, J., Mintz, J., Kane, J. M. (2014). Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. Schizophrenia Bulletin. PMID: 24870446.

Sodhi, S. K., Linder, J., Chenard, C. A., Miller, D. D., Haynes, W. G. & Fiedorowicz, J. G. (2012). Evidence for accelerated vascular aging in bipolar disorder. Journal of Psychosomatic Research, 73(3), 175-9.

Keefe, R. S., Vinogradov, S., Medalia, A., Buckley, P. F., Caroff, S. N., D'Souza, D. C., Harvey, P. D., Graham, K. A., Hamer, R. M., Marder, S. M., Miller, D. D., Olson, S. J., Patel, J. K., Velligan, D., Walker, T. M., Haim, A. J. & Stroup, S. T. (2012). Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. The Journal of Clinical Psychiatry, 73(7), 1016-22. PMID: 22687548.

Aberg, K., Adkins, D. E., Buksza, J., Webb, B. T., Caroff, S., Miller, D. D., Perkins, D., Sebat, J., Stroup, T. S., Vladimirov, V. I., McClay, J. L., Liberman, J. A., Sullivan, P. F. & van den Oord, E. J. (2012). Genome-wide association study of antipsychotic-induced QTc interval prolongation. The Pharmacogenomics Journal, 12(2), 165-72. PMID: 20921969.

Fiedorowicz, J. G., Miller, D. D., Bishop, J. R., Calarge, C. A., Ellingrod, V. L. & Haynes, W. G. (2012). Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Current Psychiatry Reviews, 8(1), 25-36. PMID: 22712004.

Kerfoot, K. E., Rosenheck, R. A., Petrakis, I. L., Swartz, M. S., Keefe, R. S., McEvoy, J. P. & Stroup, T. S. (2011). Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophrenia Research, 132(2-3), 177-82. PMID: 21872443.

Chakos, M., Patel, J. K., Rosenheck, R., Glick, I. D., Hammer, M. B., Tapp, A., Miller, A. L. & Miller, D. (2011). Concomitant psychotropic medication use during treatment of schizophrenia patients: Longitudinal results from the CATIE study. Clinical Schizophrenia & Related Psychoses, 5(3), 124-34. PMID: 21983496.

Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S. & Rosenheck, R. A. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). The American Journal of Psychiatry, 168(9), 947-56.

Prabhakar, M., Haynes, W. G., Coryell, W. H., Chrischilles, E. A., Miller, D. D., Arndt, S., Ellingrod, V. L., Warren, L. & Fiedorowicz, J. G. (2011). Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. Pharmacotherapy, 31(8), 806-12. PMID: 21923607.

Calarge, C. A., Miller, D. D. (2011). Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21(2), 163-9. PMID: 21486167.

Caroff, S. N., Davis, V. G., Miller, D. D., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M., Keefe, R., Stroup, T. S. & Liberman, J. A. (2011). Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. The Journal of Clinical Psychiatry, 72(3), 295-303.

Bishop, J. R., Miller, D. D., Ellingrod, V. L. & Holman, T. (2011). Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia. Human Psychopharmacology, 26(1), 28-34. PMID: 21344500.

Sodhi, S., Linder, J., Coryell, W. H., Miller, D. D. & Fiedorowicz, J. G. (2011). Health behaviors contribute to arterial stiffness later in the course of bipolar disorder. Poster Presented at the 50th Annual Meeting of ACNP.

Caroff, S. N., Miller, D. D., Dhopesh, V. & Campbell, E. C. (2011). Is there a rational management strategy for tardive dyskinesia?. Current Psychiatry, 10(10), 23-32.

Foster, A., Miller, D. D. & Buckley, P. (2010). Pharmacogenetics and schizophrenia. Clinics in Laboratory Medicine, 30(4), 975-93. PMID: 20832661.

Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D. D. & Kane, J. (2010). Antipsychotic Dose-Years: A Quantitative Method for Measuring Dose Equivalents and Cumulative Drug Exposure. Biological Psychiatry, 67(3), 255-262. PMID: 19897178.

Tsai, H. T., Caroff, S. N., Miller, D. D., McEvoy, J., North, K., Stroup, T. S. & Sullivan, P. F. (2010). A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. American Journal of Medical Genetics, 153B(1), 336-40.

Aberg, K., Adkins, D. E., Buksza, J., Webb, B. T., Caroff, S., Miller, D., Perkins, D., Sebat, J., Stroup, T. S., Vladimirov, V. I., McClay, J. L., Liberman, J. A., Sullivan, P. F. & Van den Oord (2010). Genome-wide association study of movement-related adverse drug effects in schizophrenic patients. Biological Psychiatry, 67(3), 279-282.

Jin, Y., Pollock, B. G., Coley, K., Miller, D. D., Marder, S. R., Florian, J., Kirshner, M. & Bies, R. R. (2010). Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race and smoking. Journal of Clinical Pharmacology, 50(1), 73-80. PMID: 19843655.

Calarge, C. A., Ellingrod, V. L., Acion, L., Miller, D. D., Moline, J., Tansey, M. J. & Schlechte, J. A. (2009). Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and Genomics, 19(5), 373-82. PMID: 19339912.

Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., Gage, A. & MEM-MD-29 Study Group (2009). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology, 34(5), 1322-9. PMID: 19005465.

Bishop, J. R., Miller, D. D., Ellingrod, V. L. & Holman, T. L. (2009). Association between GRM3 and GRIN2B gene variants and symptoms in treatment refractory schizophrenia. Abstracts of the International Congress on Schizophrenia Research Meeting.

Grove, T. B., Taylor, S. F., Moline, J., Miller, D. D., Holman, T. & Kerr, J. (2009). Pharmacogenetics of Folic Acid Metabolism and Metabolic Disturbances in Schizophrenia. Abstracts of the International Congress on Schizophrenia Research Meeting.

Ellingrod, V. L., Meden, M., Grove, T. B., Taylor, S. F., Moline, J., Miller, D. D., Holman, T. & Kerr, J. (2009). Relationship between the Adiponectin (APM1) 276G/T variant and metabolic disturbances in a schizophrenia population receiving antipsychotics. Abstracts of the International Congress on Schizophrenia Research Meeting.

Feng, Y., Pollock, B. G., Coley, K., Marder, S., Miller, D. D., Aravagiri, M., Kirshner, M. A. & Bies, R. R. (2008). Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. British Journal of Clinical Pharmacology, 66(5), 629-39. PMID: 18771484.

Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M., Keefe, R., Stroup, S. & Liberman, J. A. (2008). Extrapyramidal side-effects of antipsychotics in a randomized trial. The British Journal of Psychiatry, 193(4), 279-88. PMID: 18827289.

Fiedorowicz, J. G., Palagummi, N. M., Forman-Hoffman, V. L., Miller, D. D. & Haynes, W. G. (2008). Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Annals of Clinical Psychiatry, 20(3), 131-7. PMID: 18633739.

Swartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., Reimherr, F., Miller, D. D., McGee, M., Khan, A., Canive, J. M., Davis, S. M., Hsiao, J. K. & Liberman, J. A. (2008). The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. Schizophrenia Research, 100(1-3), 39-52. PMID: 18191383.

Bigos, K. L., Pollock, B. G., Coley, K. C., Miller, D. D., Marder, S. R., Arvagiri, M., Kirshner, M. A., Schneider, L. S. & Bies, R. R. (2008). Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology, 48(2), 157-65. PMID: 18199892.

Ellingrod, V. L., Miller, D. D., Taylor, S. F., Moline, J., Holman, T. & Kerr, J. (2008). Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophrenia Research, 98(1-3), 47-54. PMID: 17976958.

Ellingrod, V. L., Grove, T. B., Taylor, S. F., Moline, J., Miller, D. D., Holman, T., Kerr, J. & Kerr, J. (2008). Relationship Between The Methylenetetrahydrofolate Reductase (MTHFR) 677C/T And Brain Derived Neurotrophic Factor (BNDF) Val66Met Variants And Metabolic Complications Seen With Antipsychotic Use In Schizophrenia Subjects. pp. 206. Abstracts of the American College of Neuropsychopharmacology (ACNP) 47th Annual Meeting.

Miller, D. D., Eudicone, J. M., Pikalov, A., Vester-Blokland, E. & Kim, E. (2007). Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: A post hoc analysis. The Journal of Clinical Psychiatry, 68(12), 1901-1906. PMID: 18162021.

Moore, T. A., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., Essock, S. M., Finnerty, M., Marder, S. R., Miller, D. D., McEvoy, J. P., Robinson, D., Schooler, N. R., Shon, S. P., Stroup, T. S. & Miller, A. L. (2007). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of Clinical Psychiatry, 68(11), 1751-62. PMID: 18052569.

Foster, A., Miller, D. D. & Buckley, P. F. (2007). Pharmacogenetics and Schizophrenia. The Psychiatric Clinics of North America, 30(3), 417-35. PMID: 17720030.

Jin, Y., Pollock, B. G., Coley, K., Miller, D. D., Marder, S., Kirshner, M. A. & Bies, R. R. (2007). Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race, smoking and concomitant medications. Abstracts of the 3rd Great Lake Symposium.

Ellingrod, V. L., Miller, D. D., Taylor, S. F., Holman, T. L., Kerr, J. & Moline, J. (2007). Association between the Methylenetetrahydrofolate Reductase (MTHFR) 677C/T Variant and Atypical Antipsychotics (AAPs). pp. 503. Abstracts of the Sixth Annual Pharmacogenetics in Psychiatry Meeting.

Ellingrod, V. L., Bishop, J. R., Moline, J., Lin, Y. C. & Miller, D. D. (2007). Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacology Bulletin, 40(1), 57-62. PMID: 17285096.

Miller, D. D. (2007). Sedation with Antipsychotics: Manage, don't accept adverse 'calming' effect. Current Psychiatry, 6(8), 38-51.

Miller, D. D., Kim, E., Eudicone, J., Pikalov, A. A. & Vester-Blokland, E. (2007). Treatment-Emergent Tardive Dyskinesia in Patients Receiving Aripiprazole or Haloperidol for the Treatment of Schizophrenia or Schizoaffective Disorder. (Vols. 33). (2) Abstracts of the XX International Congress on Schizophrenia Research Meeting. Schizophrenia Bulletin.

Lin, Y. C., Ellingrod, V. L., Bishop, J. R. & Miller, D. D. (2006). The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Therapeutic Drug Monitoring, 28(5), 668-72. PMID: 17038883.

Keefe, R. S., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., Adler, L., Manschreck, T., Schwartz, M., Rosenheck, R. A., Perkins, D. O., Walker, T. M., Stroup, T. S., McEvoy, J. P. & Liberman, J. A. (2006). Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, 31(9), 2033-46. PMID: 16641947.

Chakos, M. H., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., Tapp, A., Keefe, R. S. & Rosenheck, R. (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Services (Washington, D.C.), 57(8), 1094-1101. PMID: 16870959.

Swartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., McGee, M., Miller, D. D., Reimherr, F., Kahn, A., Canive, J. M. & Lieberman, J. A. (2006). Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services (Washington, D.C.), 57(8), 1110-6. PMID: 16870961.

Swartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., Canive, J. M., Miller, D. D., Remiherr, F., McGee, M., Kahn, A., Van Dorn, R., Rosenheck, R. A. & Liberman, J. A. (2006). Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease, 194(3), 164-72. PMID: 16534433.

Bishop, J. R., Ellingrod, V. L., Moline, J. & Miller, D. D. (2006). Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Medical Science Monitor, 12(2), BR47-50. PMID: 16449941.

Feng, Y., Pollock, B. G., Coley, K., Marder, S. R., Aravagiri, M., Miller, D. D., Kirshner, M. A. & Bies, R. R. (2006). Assessing Sources of Variability in Risperidone Pharmacogenetics: A Population Analysis of Risperidone Using Highly Sparse Sampling Measurements from the CATIE Study. (Vols. 59). pp. 230S. Biological Psychiatry.

Chakors, M. H., Glick, I., Miller, A., Tapp, A., Hammer, M. B., Miller, D. D., Patel, J. & Rosenheck, R. (2006). Concomitant Psychotropic Medications in Treatment of Schizophrenic Patients: Baseline Use in the CATIE Trial. (Vols. 59). pp. 154S. Biological Psychiatry.

Miller, D. D., Kim, E., Eudicone, J., Pikalov, A. A., Vester-Blokland, E. & Coryell, W. H. (2006). Incidence and Severity of Tardive Dyskinesia in Patients Receiving Aripiprazole or Haloperidol for the Treatment of Schizophrenia or Schizoaffective Disorder. (Vols. 29). (Suppl. 1), pp. S175. Abstracts of the ACNP 45th Annual Meeting.

Ellingrod, V. L., Bishop, J. R., Moline, J., Lin, Y. C. & Miller, D. D. (2006). Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia. Abstracts of the fifth Annual Pharmacogenetics in Psychiatry Meeting (New York, NY).

Chew, M. L., Pollock, B. G., Coley, K., Marder, S. R., Miller, D. D. & Bies, R. R. (2006). Population Pharmacokinetic Model of Quetiapine Using Highly Sparse Data from the CATIE Study. Biological Psychiatry, 59, 74S.

Bigos, K. L., Pollock, B. G., Coley, K., Marder, S. R., Miller, D. D., Kirshner, M. A. & Bies, R. R. (2006). Sources of Variability in Olanzapine Exposure from the CATIE-AD Study. (Vols. 59). pp. 140S. Biological Psychiatry.

Miller, D. D., McEvoy, J. P., Davis, S. M., Caroff, S. N. & Saltz, B. L. (2005). Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research, 80(1), 33-43. PMID: 16171976.

Buckley, P. F., Miller, D. D., Singer, B., Arena, J. & Stirewalt, E. M. (2005). Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research, 79(2-3), 281-8. PMID: 15964743.

Bishop, J. R., Ellingrod, V. L., Moline, J. & Miller, D. D. (2005). Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophrenia Research, 77(3-Feb), 253-260. PMID: 15913960.

Perry, P. J., Argo, T. R., Carnahan, R. M., Lund, B. C., Holman, T. L., Ellingrod, V. L. & Miller, D. D. (2005). The association of weight gain and olanzapine plasma concentrations. Journal of Clinical Psychopharmacology, 25(3), 250-4. PMID: 15876904.

Ellingrod, V. L., Perry, P. J., Ringold, J. C., Lund, B. C., Bever-Stille, K., Fleming, F., Holman, T. L. & Miller, D. D. (2005). Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. American Journal of Medical Genetics, 134B(1), 76-8. PMID: 15666332.

Miller, D. D., Ellingrod, V. L., Holman, T. L., Buckley, P. F. & Arndt, S. (2005). Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. American Journal of Medical Genetics, 133B(1), 97-100. PMID: 15635667.

Miller, D. D., Ellingrod, V. L., Holman, T. L. & Buckley, P. F. (2005). 5HT2C Receptor Polymorphisms, Weigh Gain, and Clinical Response to Clozapine Treatment. (Vols. 31). (2), pp. 273. Schizophrenia Bulletin.

Ellingrod, V. L., Moline, J. & Miller, D. D. (2005). Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Abstracts of the Fourth Annual Pharmacogenetics in Psychiatry Meeting.

Keefe, R. S., Bilder, R. M., Harvey, P. D., Davis, S., Palmer, B., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J., Adler, L., Manschreck, T., Swartz, M., Rosenheck, R., Perkins, D. O., Walker, T. M., Stroup, T. S., McEvoy, J. P. & Liberman, J. A. (2005). Baseline Neurocognitive Assessment of 1364 Patients with Schizophrenia in the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Project. (Vols. 31). (2), pp. 361. Schizophrenia Bulletin.

Stirewalt, E. M., Miller, D. D., Singer, B. & Buckley, P. F. (2005). Implementing Guideline Recommendations for Managing Metabolic Effects of Antipsychotic Medications. (Vols. 31). (2), pp. 270. Schizophrenia Bulletin.

Ellingrod, V. L., Miller, D. D., Ringold, J. C. & Perry, P. J. (2004). Distribution of the serotonin 2C (5HT2C) receptor gene -759C/T polymorphism in patients with schizophrenia and normal controls. Psychiatric Genetics, 14(2), 93-5. PMID: 15167695.

Miller, A., Hall, C. S., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crimson, M. L., Ereshefsky, L., Essock, S. M., Finnerty, M., Marder, S. M., Miller, D. D., McEvoy, J., Rush, A. J., Saeed, S. A., Schooler, N. R., Shon, S., Stroup, S. & Tarin-Godoy, B. (2004). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. The Journal of Clinical Psychiatry, 65(4), 500-8. PMID: 15119912.

Miller, D. D. (2004). -759C/T and Cys23Ser Polymorphisms of the 5HT2C Receptor, weight gain, and Clinical Responses Associated with Clozapine Treatment. Third Annual Pharmacogenetics in Psychiatry Meeting.

Miller, D. D. (2004). Atypical antipsychotics: Sleep, Sedation, and Efficacy. Primary Care Companion to The Journal of Clinical Psychiatry, 6(Suppl 2), 3-7. PMID: 16001094.

Buckley, P. F., Miller, D. D., Stirewalt, E. M., Singer, B. & Arena, J. (2004). Diabetes and Antipsychotic Medication; Are we Ready?. (Vols. 29). (Suppl 1), pp. S110. Abstracts of the ACNP 43rd Annual Meeting.

Miller, D. D., Ellingrod, V. L., Holman, T. L. & Buckley, P. F. (2004). Polymorphisms of the Genes that Code for the 5HT2C Receptor, Weight Gain, and Clinical Response During Clozapine Treatment. (Vols. 29). (Suppl 1), pp. S175. Abstracts of the ACNP 43rd Annual Meeting.

Miller, D. D. (2003). Clozapine and tardive dyskinesia. The American Journal of Psychiatry, 160(3), 588. PMID: 12611849.

Ellingrod, V. L., Lund, B. C., Miller, D. D., Fleming, F. & Perry, P. (2003). 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacology Bulletin, 37(2), 109-12. PMID: 14566219.

Miller, D. D., Ellingrod, V. L. & Buckley, P. F. (2003). Clozapine-induced weight gain associated with the -759C/T polymorphism of the 5HT2C receptor. pp. 380. Abstracts of the American College of Neuropsychopharmacology.

Miller, D. D., Ellingrod, V. L., Holman, T. L., Buckley, P. F. & Singer, B. (2003). Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and clozapine. pp. 380. Abstracts of the Second Annual Pharmacogenetics in Psychiatry Meeting.

Ellingrod, V. L., Perry, P. J., Lund, B. C., Bever-Stille, K., Fleming, F., Holman, T. L. & Miller, D. D. (2002). 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. Journal of Clinical Psychopharmacology, 22(6), 622-4. PMID: 12454564.

Corson, P. W., O'Leary, D. S., Miller, D. & Andreasen, N. C. (2002). The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naive and medicated states. Biological Psychiatry, 52(9), 855-62. PMID: 12399138.

Ellingrod, V. L., Miller, D. D., Schultz, S. K., Wehring, H. & Arndt, S. (2002). CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatric Genetics, 12(1), 55-8. PMID: 11901361.

Miller, D. D., Schultz, S. K. (2002). Differential diagnosis of schizophrenia. In J. Csernansky (Eds.) Schizophrenia: A New Guide for Clinicians. pp. 53-68. Marcell Decker, Inc..

Lund, B. C., Perry, P. J. & Miller, D. D. (2001). Treating depression in schizophrenia. The American Journal of Psychiatry, 158(9), 1528-9. PMID: 11532750.

Buckley, P. F., Friedman, L., Krowinski, A. C., Eaton, Y., Tronetti, M. & Miller, D. D. (2001). Clinical and biochemical correlates of "high-dose" clozapine therapy for treatment-refractory schizophrenia. Schizophrenia Research, 49(2-Jan), 225-7. PMID: 11428347.

Miller, D. D., Andreasen, N. C., O'Leary, D. S., Watkins, G. L., Boles Ponto, L. L. & Csernansky, J. (2001). Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biological Psychiatry, 49(8), 704-15. PMID: 11313038.

Buckley, P. F., Miller, D. D., Singer, B. & Donenwirth, K. (2001). The evolving clinical profile of atypical antipsychotic medications. Canadian Journal of Psychiatry, 46(3), 285. PMID: 11320683.

Perry, P. J., Ellingrod, V. L., Bever-Stille, K. A., Lund, B. C., Miller, D. D. & Fleming, F. W. (2001). 5HT2A receptor polymorphisms and negative symptom response to olanzapine. (Vols. 49). (1-2), pp. 78. Schizophrenia Research.

Miller, D. D., O'Leary, D. S. & Andreasen, N. C. (2001). Differences in the effect of risperidone and haloperidol on rCBF in patients with schizophrenia performing a practiced memory task. pp. 380. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Nopoulos, P. C., Miller, D. D., Flaum, M. & Andreasen, N. C. (2001). Issues in the assessment of negative symptom treatment response. In Negative Symptom and Cognitive Treatment Response in Schizophrenia. pp. 19-32. American Psychiatric Press.

Ellingrod, V. L., Miller, D. D., Schultz, S. K., Arndt, S. & Wehring, H. J. (2001). Polymorphisms of CYP2D6 as a risk factor for weight gain with olanzapine. (Vols. 49). (1-2), pp. 283. Schizophrenia Research.

Miller, D. D., Tandon, R. (2001). The biology and pathophysiology of negative symptoms. In Negative Symptom and Cognitive Treatment Response in Schizophrenia. pp. 163-186. American Psychiatric Press.

Buckley, P., Miller, A., Olsen, J., Garver, D. & Miller, D. D. (2001). When symptoms persist: Clozapine augmentation strategies. Schizophrenia Bulletin, 27(4), 615-28. PMID: 11824488.

Ho, B. C., Andreasen, N. C., Flaum, M., Nopoulos, P. & Miller, D. (2000). Untreated initial psychosis: Its relation to quality of life and symptom remission in first-episode schizophrenia. The American Journal of Psychiatry, 157(5), 808-15. PMID: 10784476.

Miller, D. D., O'Leary, D. S. & Andreasen, N. C. (2000). Differences in the effect of risperidone and haloperidol on rCBF in patients with schizophrenia performing a practiced memory task. pp. 312. Abstracts of the American College of Neuropsychoparmacology (ACNP) 39th Annual Meeting.

Miller, D. D. (2000). Optimization of clozapine treatment. pp. 52. Abstracts of the American Psychiatric Association (APA) Annual Meeting.

Miller, D. D. (2000). Review and management of clozapine side effects. The Journal of Clinical Psychiatry, 61 Suppl 8, 14-7; discussion 18-9. PMID: 10811238.

Ho, B. C., Miller, D., Nopoulos, P. & Andreasen, N. C. (1999). A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. The Journal of Clinical Psychiatry, 60(10), 658-63. PMID: 10549681.

Andreasen, N. C., Nopoulos, P., O'Leary, D. S., Miller, D. D. & Wassink, T. (1999). Defining the phenotype of schizophrenia: Cognitive dysmetria and its neural mechanisms. Biological Psychiatry, 46(7), 908-20. PMID: 10509174.

Corson, P. W., Nopoulos, P., Miller, D. D., Arndt, S. & Andreasen, N. C. (1999). Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. The American Journal of Psychiatry, 156(8), 1200-4. PMID: 10450260.

Meltzer, H. Y., Casey, D. E., Garver, D. C., Lasagna, L., Marder, S. R. & Masand, P. S. (1999). Clinical trial evaluations and outcome measures in psychiatry. Journal of Clinical Psychiatry, 59(12), 1-1.

Miller, D. D., O'Leary, D. S. & Andreasen, N. C. (1999). Comparison of the effect of haloperidol and resperidone on regional cerebral blood flow in schizophrenia. (Vols. 36). (3), pp. 228. Schizophrenia Research.

Miller, D. D., O'Leary, D. S. & Andreasen, N. C. (1999). Comparison of the effects of haloperidol and risperidone on rCBF in patients with schizophrenia performing a complex narrative task. pp. 278. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Schultz, S. K., Miller, D. D. (1999). Effects of aging on psychotropic efficacy and toxicity. In Psychiatric Treatment in the Medically Ill. pp. 499-521. Marcell Decker, Inc..

Flaum, M. A., Magnotta, V., Sears, L., Arndt, S., O'Leary, D. S., Miller, D. D. & Andreasen, N. C. (1999). Effects of olanzapine on regional cerbral blood flow as assessed by functional magnetic resonance imaging in patients with schizophrenia. (Vols. 36). (3), pp. 221. Schizophrenia Research.

Miller, D. D., Schooler, N. R., Kane, J. M., Marder, S. R., Miller, A. L., Conley, R. R., Essock, S., Volavka, J. V., Glick, I. D. & Davis, J. M. (1999). New methodological issues in the study of treatment-refractory schizophrenia. pp. 41. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Miller, D. D., O'Leary, D. S. & Andreasen, N. C. (1999). The relationship between haloperidol dose and regional cerebral blood flow in persons with schizophrenia. (Vols. 36). (6), pp. 228. Schizophrenia Research.

Buckely, P. F., Miller, D. D., Singer, B. & Donenwirth, K. (1999). What's new with the new antipsychotics. pp. 202. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Westmoreland Corson, P., Miller, D. D., O'Leary, D. & Andreasen, N. C. (1998). Cerebral Blood flow in the caudate and putamen of neuroleptic naïve schizophrenic patients. pp. 333. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Miller, D. D., O'Leary, D. S. & Andreasen, N. C. (1998). Comparison of the effect of haloperidol and resperidone on regional cerebral blood flow in schizophrenia. pp. 336. Abstracts of the American Colleg of Neuropsychopharmacology.

Miller, D. D., O'Leary, D. S., Cizaldo, T. & Andreasen, N. C. (1998). Comparison of the effect of typical and atypical antipsychotics on regional cerebral blood flow in schizophrenia. Abstracts of the Congress of the Collegium Internationale Neuropsychopharmacologicum (CINP) 21st Annual Meeting.

Coryell, W., Miller, D. D. & Perry, P. J. (1998). Haloperidol plasma levels and dose optimization. The American Journal of Psychiatry, 155(1), 48-53. PMID: 9433338.

Ho, B. C., Miller, D. D. & Andreasen, N. C. (1998). The Efficacy of Risperidone in the Maintenance Treatment of Patients with Recent-onset Schizophrenia. Abstracts of the Congress of the Collegium Internationale Neuropsychopharmacologicum (CINP) 21st Annual Meeting.

Miller, D. D., Andreasen, N. C., O'Leary, D. S., Rezai, K. & Watkins, G. L. (1997). Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology, 17(4), 230-40. PMID: 9326747.

Miller, D. D., Rezai, K., Alliger, R. & Andreasen, N. C. (1997). The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography. Biological Psychiatry, 41(5), 550-9. PMID: 9046987.

Miller, D. D., O'Leary, D. S., Cizaldo, T., Hichwa, R. D. & Andreasen, N. C. (1997). Comparison of the effect of typical and atypical antipsychotics on regional cerebral blood flow in schizophrenia. pp. 298. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Andreasen, N. C., Flaum, M., Schultz, S., Duzyurek, S., Miller, D. D. & Andreasen, N. C. (1997). Diagnosis, methodology and subtypes of schizophrenia. Neuropsychobiology, 35(2), 61-3. PMID: 9097293.

Schultz, S., Miller, D. D., Arndt, S. V. & Andreasen, N. C. (1997). Effects of low versus high potency neuroleptic withdrawal on symptoms and dyskinetic movements. (Vols. 24). pp. 266. Schizophrenia Research.

Buckely, P. F., Miller, D. D., Richman, C., Chapman, P., Negron, A. & Friedman, L. (1997). Electroencephalographic pattern, side-effect profile and clozapine plasma levels in patients receiving 900 mg of clozapine. (Vols. 24). pp. 264. Schizophrenia Research.

Miller, D. D. (1997). Long-term use of atypical antipsychotics. Abstracts of the 150th Annual Meeting of the American Psychiatric Association.

Miller, D. D., Ziebell, S., Nopoulos, P. & Andreasen, N. C. (1997). Risperidone versus haloperidol in a longitudinal follow-up of recent-onset schizophrenia. (Vols. 24). pp. 195. Schizophrenia Research.

Schultz, S. K., Miller, D. D., Oliver, S. E., Arndt, S. & Flaum, M. (1997). The life course of schizophrenia: Age and symptom dimensions. Schizophrenia Research, 23(1), 15-23. PMID: 9050124.

Miller, D. D. (1996). Sedation--therapeutic or side effect in psychoses. Pharmacotherapy, 16(6 Pt 2), 141S-142S. PMID: 8947996.

Consensus Study Group on Risperidone Dosing, Borison, R. L., Romano, S., Daniel, D. G., Davidson, J., DeVane, C. L., Hansen, M. S., Horne, R., Miller, D. D. & Remington, G. (1996). Changing antipsychotic medication: Guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Clinical Therapeutics, 18(4), 592-607; discussion 591. PMID: 8879889.

Miller, D. D. (1996). The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Annals of Clinical Psychiatry, 8(2), 99-109. PMID: 8807035.

Miller, D. D., Schultz, S. & Alexander, B. (1996). Rational Pharmacological Approaches in the Management of Treatment-Resistant Schizophrenia. Psychiatric Clinics of North America, 3, 89-118.

Miller, D. D., Ziebell, S., Nopoulos, P. & Andreasen, N. C. (1996). Risperidone versus haloperidol in a naturalistic follow-up of recent-onset schizophrenia. Abstracts of the American College of Neuropsychopharmacology.

Miller, D. D. (1996). Schizophrenia: Its Etiology and Impact. Pharmacotherapy, 16(1 Pt 2), 2-5. PMID: 8778683.

Schultz, S. K., Miller, D. D., Arndt, S., Ziebell, S., Gupta, S. & Andreasen, N. C. (1995). Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biological Psychiatry, 38(11), 713-9. PMID: 8580223.

Flaum, M., O'Leary, D. S., Swayze, V. W., Miller, D. D. & Arndt, S. (1995). Symptom dimensions and brain morphology in schizophrenia and related psychotic disorders. Journal of Psychiatric Research, 29(4), 261-76. PMID: 8847654.

Arndt, S., Andreasen, N. C., Flaum, M., Miller, D. D. & Nopoulos, P. (1995). A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Archives of General Psychiatry, 52(5), 352-60. PMID: 7726715.

Andreasen, N. C., Arndt, S., Alliger, R., Miller, D. D., Flaum, M. & Andreasen, N. C. (1995). Symptoms of schizophrenia. Methods, meanings, and mechanisms. Archives of General Psychiatry, 52(5), 341-51. PMID: 7726714.

Buckley, P. F., Krowinski, A. C., Miller, D. D., Friedman, L., Eaton, Y. & Tronetti, M. (1995). Clozapine plasma levels and clinical efficacy at 900 mg dose. Abstracts of the American College of Neuropsychopharmacology (ACNP) 34th Annual Meetign.

Andreasen, N. C., Arndt, S., Miller, D. D., Flaum, M. & Nopoulos, P. (1995). Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: an overview and update. Psychopathology, 28(1), 7-17. PMID: 7871123.

Schultz, S., Travis, K., Ziebell, S., Miller, D. D., Arndt, S. & Andreasen, N. C. (1995). Polydipsia and schizophrenia: A comparison of neuroleptic-naïve and treated patients. (Vols. 15). pp. 165. Schizophrenia Research.

Schultz, S., Zeibell, S., Miller, D. D., Arndt, S. & Andreasen, N. C. (1995). Schizophrenia and aging: A comparison of symptoms. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Coryell, W. H., Miller, D. D. & Perry, P. J. (1995). The clinical utility of haloperidol plasma levels. (Vols. 15). pp. 146. Schizophrenia Research.

Miller, D. D., Flaum, M. A., Nopoulos, P., Arndt, S. & Andreasen, N. C. (1995). The concept of dose years: A reliable method for calculating lifetime psychotropic drug exposure. (Vols. 15). pp. 159. Schizophrenia Research.

Miller, D. D., O'Leary, D. S., Hichwa, R. D., Nopolous, P. & Andreasen, N. C. (1995). The effect of antipsychotic medication on PET studies of cerebral blood flow during tasks assessing language and memory in schizophrenia. (Vols. 15). pp. 92. Schizophrenia Research.

Beck, D. A., Miller, D. D. (1994). Clozapine-associated neutropenic enterocolitis. Annals of Clinical Psychiatry, 6(3), 185-8. PMID: 7881499.

Miller, D. D., Fleming, F., Holman, T. L. & Perry, P. J. (1994). Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. The Journal of Clinical Psychiatry, 55 Suppl B, 117-21. PMID: 7961554.

Miller, D. D., Flaum, M., Arndt, S., Fleming, F. & Andreasen, N. C. (1994). Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology, 11(1), 11-20. PMID: 7945739.

Andreasen, N. C., Miller, D. D., Flaum, M., Schultz, S., Nopolous, P. & Gupta, S. (1994). Assessing and Treating the Negative Symptoms of Schizophrenia. (Vols. 10). (3S), pp. 70S. Neuropsychopharmacology.

Miller, D. D., Perry, P. J., Cadoret, R. J. & Andreasen, N. C. (1994). Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Comprehensive Psychiatry, 35(1), 8-15. PMID: 8149734.

Miller, D. D., Perry, P. J., Cadoret, R. J. & Andreasen, N. C. (1994). Clozapine's effect on negative symptoms in treatment-resistant schizophrenics. (Vols. 2). (4), pp. 88-91. Focus on Psychiatry 2.

Andreasen, N. C., Miller, D. D., Nopoulos, P., Schultz, S., Gupta, S. & Flaum, M. (1994). Issues in the Assessment of Negative Symptoms. Abstracts of the 150th Annual Meeting of the American Psychiatric Association.

Andreasen, N. C., Nopoulos, P., Schultz, S., Miller, D. D., Gupta, S., Swayze, V. & Flaum, M. (1994). Positive and negative symptoms of schizophrenia: Past, present, and future. Acta psychiatrica Scandinavica, 384, 51-9. PMID: 7879644.

Andreasen, N. C., Arndt, S., Miller, D. D., Flaum, M. A., O'Leary, D. S. & Nopolous, P. (1994). The Clinical and Biological Significance of Negative and Affective Symptoms. (Vols. 10). (3S), pp. 150S. Neuropsychopharmacology.

Miller, D. D., O'Leary, D. S., Hichwa, R. D., Nopolous, P. & Andreasen, N. C. (1994). The effect of antipsychotic medication on PET studies of cerebral blood flow during tasks assessing language and memory in schizophrenia. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Ziebell, S., Miller, D. D. & Andreasen, N. C. (1994). Withdrawal-Emergent Dyskinesia in Patients with Schizophrenia During Antipsychotic Discontinuation. Abstracts of the 150th Annual Meeting of the American Psychiatric Association.

Miller, D. D., Arndt, S. & Andreasen, N. C. (1993). Alogia, attentional impairment, and inappropriate affect: their status in the dimensions of schizophrenia. Comprehensive Psychiatry, 34(4), 221-6. PMID: 8348799.

Perry, P. J., Miller, D. D., Arndt, S. V., Smith, D. A. & Holman, T. L. (1993). Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. Journal of Clinical Psychopharmacology, 13(1), 46-51. PMID: 8486817.

Miller, D. D., Arndt, S. & Andreasen, N. C. (1993). Alogia, Attentional Impairment, And Inappropriate Affect: Their Status In The Dimension of Schizophrenia. (Vols. 9). pp. 104. Schizophrenia Research.

Miller, D. D., Perry, P. J., Cadoret, R. J. & Andreasen, N. C. (1993). Clozapine's Effect On Negative Symptoms In Treatment-Refractory Schizophrenia. (Vols. 9). pp. 245. Schizophrenia Research.

Andreasen, N. C., Flaum, M. A., Arndt, S. V., Miller, D. D., Nopolous, P. & O'Leary, D. S. (1993). Dimensions of Psychopathology in Schizophrenia: Evolution Over Time. Abstracts of the American College of Neuropsychopharmacology (ACNP).

Arndt, S., Davis, C. S., Miller, D. D. & Andreasen, N. C. (1993). Effect of antipsychotic withdrawal on extrapyramidal symptoms: statistical methods for analyzing single-sample repeated-measures data. Neuropsychopharmacology : Official publication of the American College of Neuropsychopharmacology, 8(1), 67-75. PMID: 8093835.

Swayze, V. W., Andreasen, N. C., O'Leary, D., Flaum, M. A., Sickels, W., Miller, D. D. & Ziebell, S. (1993). Long-Term Follow-Up Study of Frontal Lobotomy in Schizophrenia. (Vols. 9). pp. 210. Schizophrenia Research.

Miller, D. D., Arndt, S. & Andreasen, N. C. (1993). Negative Symptoms in Antipsychotic-Naïve Schizophrenia Patients and The Effect of Haloperidol Treatment. Abstracts of the 150th Annual Meeting of the American Psychiatric Press.

Andreasen, N. C., Swayze, V. W., O'Leary, D., Miller, D. D., Flaum, M. A. & Gupta, S. (1993). Structural Brain Abnormalities Revisited: Measurement Of Volumes And Surface Strcutures Based On Three-Dimensional Magnetic Resonance. (Vols. 9). pp. 191. Schizophrenia Research.

Perry, P. J., Miller, D. D. (1993). The clinical utility of clozapine plasma concentrations. In Clinical Use of Neuroleptic Plasma Levels. pp. 85-100. American Psychiatric Press.

Miller, D. D. (1993). What Are the Advantages Of The New Antipsychotic Drug Risperidone?. The Harvard Mental Health Letter, 10, 8.

Miller, D. D., Perry, P. J., Cadoret, R. J. & Andreasen, N. C. (1992). A Two and One-Half Year Follow Up of Treatment-Refractory Schizophrenics Treated With Clozapine. (Vols. 31). pp. 85A. Biological Psychiatry.

Perry, P. J., Cadoret, R. J., Andreasen, N. C. & Miller, D. D. (1992). Follow-Up of Clozapine Treated Schizophrenics. Abstracts of the 145th Annual Meeting of the American Psychiatric Association.

Miller, D. D. (1992). Negative symptome und therapeutische strategien bei schizophrenie. In Schizophrenie-aktuelle Trends und Behandlungs-strategien. pp. 73-82. Springer-Verlag.

Andreasen, N. C., Miller, D. D., O'Leary, D., Flaum, M. & Rezai, K. (1992). Pleasure and anhedonia: Definition and neural substrates.

Andreasen, N. C., Flaum, M., Arndt, S. V., Alliger, R., Miller, D. D. & O'Leary, D. (1992). Positive and negative symptoms and syndromes: Assessment and biological correlates. In Nosology in Contemporary Psychiatry. pp. 79-87. John Libbey CIC.

Flaum, M., Arndt, S., Alliger, R., Miller, D. D. & O'Leary, D. (1992). Pozitif ve Negatif Belirti ve Sendromlar: Degerlendirme ve Biyolojik Karsiliklari. Turk Psikyatri Dergisi, 3, 171-176.

Miller, D. D., Alliger, R., Rezai, K. & Andreasen, N. C. (1992). The Effect of Antipsychotic Medication on Regional Blood Flow in Schizophrenia; Assessment Tc99m HMPAO SPECT. Abstracts of the American College of Neuropharmacology (ACNP) 31st Annual Meeting.

Miller, D. D., Sharafuddin, M. J. & Kathol, R. G. (1991). A case of clozapine-induced neuroleptic malignant syndrome. The Journal of Clinical Psychiatry, 52(3), 99-101. PMID: 1672311.

Perry, P. J., Miller, D. D., Arndt, S. V. & Cadoret, R. J. (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. The American Journal of Psychiatry, 148(2), 231-5. PMID: 1670979.

Miller, D. D., Flaum, M. A. & Andreasen, N. C. (1991). A Magnetic Resonance Imaging Study Comparing Treatment-Refractory and Treatment-Responsive Schizophrenics. (Vols. 4). pp. 406. Schizophr Research.

Miller, D. D., Flaum, M. A., Coryell, W. H. & Andreasen, N. C. (1991). A Magnetic Resonance Imaging Study In Schizophrenia Comparing Treatment Responses. (Vols. 29). pp. 43A-44A. Biological Psychiatry.

Andreasen, N. C., Flaum, M., Miller, D. D., Ehrhardt, J., Rezai, K., Cohen, G. & O'Leary, D. (1991). Clinical heterogeneity of schizophrenia: Perspectives from Neuroimaging. In Biological Psychiatry. pp. 455-457. Elsevier Science Publishers.

Miller, D. D. (1991). Effect of phenytoin on plasma clozapine concentrations in two patients. The Journal of Clinical Psychiatry, 52(1), 23-5. PMID: 1988414.

Andreasen, N. C., O'Leary, D., Flaum, M. A., Sickels, W., Peterson, R. & Miller, D. D. (1991). Effects of Leucotomy Lesion Size and Location on Personality and Intellect. (Vols. 4). pp. 395. Schizophr Research.

Miller, D. D., Swayze, V. W., O'Leary, D. & Andreasen, N. C. (1991). Negative Symptoms in Schizophrenia: Phenomenology and Neuroimaging. Abstracts of the 144th Annual Meeting of the American Psychiatric Press.

Lovdahl, M. J., Perry, P. J. & Miller, D. D. (1991). The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Therapeutic Drug Monitoring, 13(1), 69-72. PMID: 2057995.

Miller, D. D., Flaum, M. A., Arndt, S. V., Fleming, F. & Andreasen, N. C. (1991). The Effect of Antipsychotic Discontinuation on the Positive and Negative Symptoms of Schizophrenia. Abstracts of the American College of Neuropharmacology (ACNP).

Perry, P. J., Miller, D. D. & Coryell, W. H. (1991). The Influence of Cigarette Smoking on Haloperidol Dosing Requirements. (Vols. 4). pp. 292. Schizophr Research.

Coryell, W., Kelly, M., Perry, P. J. & Miller, D. D. (1990). Haloperidol plasma levels and acute clinical change in schizophrenia. Journal of Clinical Psychopharmacology, 10(6), 397-402. PMID: 2286709.

Miller, D. D., Kelly, M. W., Perry, P. J. & Coryell, W. H. (1990). The influence of cigarette smoking on haloperidol pharmacokinetics. Biological Psychiatry, 28(6), 529-31. PMID: 2223923.

Miller, D. D., Perry, P. J., Kelly, M. W. & Coryell, W. H. (1990). Pharmacokinetic protocol for predicting plasma haloperidol concentrations. Journal of Clinical Psychopharmacology, 10(3), 207-12. PMID: 2376619.

Nopoulos, P., Flaum, M. & Miller, D. D. (1990). Atypical Neuroleptic Malignant Syndrome with an Atypical Neuroleptic. Annals of Clinical Psychiatry, 2, 251-253.

Miller, D. D., Arndt, S. V. & Cadoret, R. J. (1990). Clozapine and Norclozapine Plasma Concentrations and Clinical Response in Treatment-Refractory Schizophrenics. Abstracts of the 30th Annual New Clinical Drug Evaluation Unit (NCDEU).

Miller, D. D., Perry, P. J. & Cadoret, R. J. (1990). Clozapine Plasma Concentrations and Clinical Response. Abstracts of the American Psychiatric Association Annual Meeting.

Kelly, M. W., Coryell, W. H., Perry, P. J. & Miller, D. D. (1990). Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. Psychopharmacology, 102(4), 514-20. PMID: 2096408.

Miller, D. D., Perry, P. J., Cadoret, R. J. & Andreasen, N. C. (1990). The Relationship Between Positive and Negative Symptoms and Clozapine Plasma Concentrations in Treatment-Refractory Schizophrenics. Abstracts of the American College of Neuropharmacology (ACNP).

Hershey, L. A., Miller, D. D. (1985). Adverse Psychiatric Drug Reactions. Neurology and Neurosurgery Update Series, 5(34), 1-8.

Hassan, E., Miller, D. D. (1985). Toxicity and elimination of trazodone after overdose. Clinical Pharmacy, 4(1), 97-100. PMID: 3971693.

Miller, D. D., Hershey, L. A., Duffy, J. P., Abernethy, D. R. & Greenblatt, D. J. (1984). Serum haloperidol concentrations and clinical response in acute psychosis. Journal of Clinical Psychopharmacology, 4(6), 305-10. PMID: 6511996.

Abernethy, D. R., Greenblatt, D. J., Ochs, H. R., Willis, C. R., Miller, D. D. & Shader, R. I. (1984). Haloperidol determination in serum and cerebrospinal fluid using gas--liquid chromatography with nitrogen--phosphorus detection: Application to pharmacokinetic studies. Journal of Chromatography, 307(1), 194-9. PMID: 6725485.

Miller, D. D., Sawyer, J. B. & Duffy, J. P. (1983). Cimetidine's effect on steady-state serum nortriptyline concentrations. Drug Intelligence & Clinical Pharmacy, 17(12), 904-5. PMID: 6653407.

Miller, D. D., Macklin, M. (1983). Cimetidine-imipramine Interaction: A Case Report. The American Journal of Psychiatry, 140(3), 351-2. PMID: 6829810.

Miller, D. D., Andorn, A. C., Stern, S. & Seideman, E. (1983). The Average Daily Dose of Antipsychotic Drugs as Clinically Prescribed in an Inpatient Setting. Society for Neuroscience Abstracts, 9, 432.

Hershey, L. A., Miller, D. D., Duffy, J. P., Gift, T. & Rivera-Camlimlim, L. (1983). Usefulness of Drug Levels in Monitoring Adverse Neurologic Effects of Antipsychotic Agents. Neurology, 33(Suppl. 2), 69.

Perry, P. J., Alexander, B., Dunner, F. J., Schoenwald, R. D., Pfohl, B. & Miller, D. D. (1982). Pharmacokinetic protocol for predicting serum lithium levels. Journal of Clinical Psychopharmacology, 2(2), 114-8. PMID: 7076875.

Blouin, R. A., Bauer, L. A., Miller, D. D., Record, K. E. & Griffen, W. O. (1982). Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrobial Agents and Chemotherapy, 21(4), 575-80. PMID: 7081978.

Miller, D. D., Love, D. W. (1980). Drug Therapy Reviews: Evaluation of minoxidil. American Journal of Hospital Pharmacy, 37(6), 808-14. PMID: 6994495.

Miller, D. D. (1980). A New Alternative for Severe Hypertension.

Gustafson, M. E., Miller, D. D., Davis, P. J. & Rosazza, J. P. (1977). Steriochemistry of the Side-Chain Dehydration of N-Benzylaxycarbonyl (S)-tryptophan by Chromobacterium Violaceum. Chemical Communications, 842-843.